Reich, Kristian, Eric L Simpson, Richard Langley, Richard B Warren, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Le Gjerum, Anna Carlsson, Melinda Gooderham, Andreas Pinter, Marjolein de Bruin-Weller, and Andrew Blauvelt. 2022. “Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest”. SKIN The Journal of Cutaneous Medicine 6 (6):s79. https://doi.org/10.25251/skin.6.supp.79.